R. Ravi Shankar

R. Ravi Shankar

Auto-generated profile, based on publicly available information

R. Ravi Shankar

Merck & Co., Inc Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Journal of Hepatology
Verified
Journal Article
Open access
MRManuel Romero-Gómez
Manuel Romero-Gómez
ELEric Lawitz
Eric Lawitz
RSR. Ravi Shankar
R. Ravi Shankar
ECEirum Chaudhri
Eirum Chaudhri
JLJie Liu
Jie Liu
JVJohn Moore Vierling
John Moore Vierling
This study assessed the effects of the GLP-1/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with nonalcoholic fatty liver disease (NAFLD). This was a Phase 2a, randomized, active-comparator-controlled, parallel-group, open-label study. A magnetic resonance imaging-estimated proton density fat fraction assessment was performed to determine LFC at screening and Week 24. Participants with an LFC of ≥10% at screening were randomized 1:1 to open-label efinopegdutide 10 mg subcutaneous (SC) once weekly or semaglutide 1 mg SC once weekly for 24 weeks, stratified according to concurrent diagnosis of type 2 diabetes. Both drugs were titrated to the target dose over an 8-week time period. The primary efficacy endpoint was relative reduction from baseline in LFC (%) after 24 weeks of treatment. Among 145 randomized participants (efinopegdutide N=72, semaglutide N=73), 33.1% had T2DM. At baseline, mean body mass index was 34.3 kg/m2and mean LFC was 20.3%. The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p<0.001) greater with efinopegdutide (72.7% [90% CI: 66.8, 78.7]) than with semaglutide (42.3% [90% CI: 36.5, 48.1]). Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs semaglutide 7.1%; p=0.085). Slightly higher incidences of adverse events and drug-related adverse events were observed in the efinopegdutide group compared with the semaglutide group, primarily related to an imbalance in gastrointestinal adverse events. In patients with NAFLD, treatment with efinopegdutide 10 mg weekly led to a significantly greater reduction in LFC than semaglutide 1 mg weekly. (EudraCT: 2020-005136-30; NCT: 04944992) IMPACT AND IMPLICATIONS: Currently, there are no approved therapies for nonalcoholic steatohepatitis (NASH). The weight loss associated with glucagon-like peptide-1 (GLP-1) receptor agonists has been shown to decrease hepatic inflammation in patients with NASH. In addition to reducing liver fat content (LFC) indirectly through weight loss, glucagon receptor agonism may also reduce LFC by acting on the liver directly to stimulate fatty acid oxidation and reduce lipogenesis. This study demonstrated that treatment of nonalcoholic fatty liver disease (NAFLD) patients with the GLP-1/glucagon receptor co-agonist efinopegdutide at 10 mg weekly led to a significantly greater reduction in LFC compared with the GLP-1 receptor agonist semaglutide at 1 mg weekly, suggesting that efinopegdutide may be an effective treatment for NASH. EudraCT: 2020-005136-30; NCT: 04944992.

7 March 2017 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
ENEberhard Nieschlag
Eberhard Nieschlag
PBPierre-Marc G. Bouloux
Pierre-Marc G. Bouloux
BSBarbara J. Stegmann
Barbara J. Stegmann
RSR. Ravi Shankar
R. Ravi Shankar
YGYanfen Guan
Yanfen Guan
HBHermann M. Behre
Hermann M. Behre
Hypogonadotropic hypogonadism (HH) in men results in insufficient testicular function and deficiencies in testosterone and spermatogenesis. Combinations of human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (recFSH) have been successful in the treatment of HH. Corifollitropin alfa is a long-acting FSH-analog with demonstrated action in women seeking infertility care. The aim of this study was to investigate the efficacy and safety of corifollitropin alfa combined with hCG to increase testicular volume and induce spermatogenesis in men with HH. This was a Phase III, multi-center, open-label, single-arm trial of corifollitropin alfa in azoospermic men aged 18 to 50 years with HH. After 16 weeks of pretreatment of 23 subjects with hCG alone, 18 subjects with normalized testosterone (T) levels who remained azoospermic entered the 52-week combined treatment phase with hCG twice-weekly and 150 μg corifollitropin alfa every other week. The increase in testicular volume (primary efficacy endpoint) and induction of spermatogenesis resulting in a sperm count ≥1 × 106/mL (key secondary efficacy endpoint) during 52 weeks of combined treatment were assessed. Safety was evaluated by the presence of anti-corifollitropin alfa antibodies and the occurrence of adverse events (AEs). Mean (±SD) testicular volume increased from 8.6 (±6.09) mL to 17.8 (±8.93) mL (geometric mean fold increase, 2.30 [95% CI: 2.03, 2.62]); 14 (77.8%) subjects reached a sperm count ≥1 × 106/mL. No subject developed confirmed anti-corifollitropin alfa antibodies during the trial. Treatment was generally well tolerated. Corifollitropin alfa 150 μg administrated every other week combined with twice-weekly hCG for 52 weeks increased testicular volume significantly, and induced spermatogenesis in >75% of men with HH who had remained azoospermic after hCG treatment alone. ClinicalTrials.gov: NCT01709331 .

28 March 2015 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
CMChantal Mathieu
Chantal Mathieu
RSR. Ravi Shankar
R. Ravi Shankar
DLDaniel Lorber
Daniel Lorber
GUGuillermo Umpierrez
Guillermo Umpierrez
FWFan Wu
Fan Wu
SESamuel S. Engel
Samuel S. Engel
Introduction The objective of this study was to assess the effect of sitagliptin on insulin dose in patients with inadequately controlled type 2 diabetes who titrate basal insulin to a target fasting glucose level after initiating sitagliptin. Methods This was a multicenter, randomized, double-blind, placebo-controlled, 24-week clinical trial in which treatment with sitagliptin 100 mg/day or placebo was administered concurrently with insulin glargine titration, targeting a fasting glucose of 4.0–5.6 mmol/L (72–100 mg/dL). The trial randomized 660 patients with type 2 diabetes and inadequate glycemic control on insulin, with or without metformin (≥1500 mg/day) or sulfonylurea, for ≥10 weeks. Patients could remain on metformin but not sulfonylurea after randomization. Results The increase from baseline in the daily dose of insulin was less in the sitagliptin group (N = 329) compared to placebo (N = 329) (between group difference = −4.7 IU [95% confidence interval [CI] −8.3, −1.2]; p = 0.009). Patients in the sitagliptin group had lower glycated hemoglobin (HbA1c) levels after 24 weeks (between-group difference of −0.4% [95% CI −0.6, −0.3; −4.9 mmol/mol (95% CI −6.6, −3.2)]; p < 0.001), and more patients in the sitagliptin group reached the HbA1c goal of <7.0% (53 mmol/mol), with a between-group difference of 17.3% (95% CI 10.4%, 24.1%; p < 0.001). Fewer patients in the sitagliptin group experienced an adverse event of hypoglycemia (between-group difference = −15.5%, p < 0.001). Conclusion Administration of sitagliptin prior to intensive titration of basal insulin glargine reduces the insulin dose requirement while providing superior glycemic control and less hypoglycemia, compared to an insulin-only regimen. Funding Merck & Co., Inc., Kenilworth, NJ, USA.

19 May 2016 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
LJLinong Ji
Linong Ji
PHPing Han
Ping Han
XWXiaoyue Wang
Xiaoyue Wang
JLJingdong Liu
Jingdong Liu
SZShaoxiong Zheng
Shaoxiong Zheng
RSR. Ravi Shankar
R. Ravi Shankar
Introduction: The results of a clinical trial to evaluate the efficacy and safety of initial combination therapy with sitagliptin and metformin in Chinese patients with type 2 diabetes and inadequate glycemic control are reported here.Materials and Methods: This was a multicenter, randomized, double‐blind, placebo‐controlled, parallel group, 24‐week clinical trial carried out in China. Patients (n = 744) with type 2 diabetes and inadequate glycemic control (glycated hemoglobin ≥7.5 and ≤11.0%) who were either drug‐naïve or washed out of previous therapy were randomized in equal ratios to sitagliptin 100 mg once daily (q.d.; S100), metformin 500 mg twice daily (b.i.d.; M1000), metformin 850 mg b.i.d. (M1700), sitagliptin 50 mg b.i.d. plus metformin 500 mg b.i.d. (S100/M1000), sitagliptin 50 mg b.i.d. plus metformin 850 mg b.i.d. (S100/M1700), or placebo.Results: The mean baseline glycated hemoglobin in randomized patients was 8.7%. Least squares mean changes from baseline in glycated hemoglobin were −0.59% (placebo), −0.99% (S100), −1.29% (M1000), −1.56% (M1700), −1.67% (S100/M1000) and −1.83% (S100/M1700) (P < 0.05 for each active group vs placebo, for S100/M1700 and S100/M1000 vs S100, and for S100/M1000 vs M1000). All treatments were generally well‐tolerated. The overall incidence of hypoglycemia (symptomatic or asymptomatic) was higher in the two co‐administration groups (S100/M1700 and S100/M1000) compared with the placebo. The incidence of symptomatic hypoglycemia was low, and similar, across all treatment groups. The incidences of gastrointestinal adverse events were generally higher in high‐dose metformin groups than in the placebo group.Conclusions: In Chinese patients with type 2 diabetes, initial combination therapy with sitagliptin and metformin was generally well‐tolerated, and provided improvement in glycemic control.

14 November 2021 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
Muhammad Yazid JalaludinMuhammad Yazid Jalaludin
Muhammad Yazid Jalaludin
ADAsma Deeb
Asma Deeb
PZPhilip Zeitler
Philip Zeitler
RGRaymundo Garcia
Raymundo Garcia
RNRon S. Newfield
Ron S. Newfield
RSR. Ravi Shankar
R. Ravi Shankar

14 November 2021 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
RSR. Ravi Shankar
R. Ravi Shankar
PZPhilip Zeitler
Philip Zeitler
ADAsma Deeb
Asma Deeb
Muhammad Yazid JalaludinMuhammad Yazid Jalaludin
Muhammad Yazid Jalaludin
RGRaymundo Garcia
Raymundo Garcia
KKKeith D. Kaufman
Keith D. Kaufman